{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:02:21Z","timestamp":1790017341010,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Specialized Diseases Clinical Research Fund of Jiangsu Province Hospital"},{"name":"Major Project of Changzhou Medical Center, Nanjing Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunochemotherapy has emerged as a promising strategy for locally advanced gastric and gastroesophageal junction (G\/EGJ) adenocarcinoma, but a substantial proportion of patients derive limited benefit. Thymalfasin is an immunomodulatory peptide that may amplify antitumor immunity while attenuating toxicity. We conducted a phase II trial to evaluate anti-PD-1 plus SOX (S-1 and oxaliplatin) immunochemotherapy combined with thymalfasin as neoadjuvant treatment for G\/EGJ adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The prospective trial enrolled patients aged 18\u201375 with cStage III G\/EGJ adenocarcinoma, ECOG 0\u20131, and adequate organ function. Treatment included three 21-day cycles of serplulimab (anti-PD-1) plus SOX (S-1 and oxaliplatin) and 9\u00a0weeks of thymalfasin, followed by curative gastrectomy. The primary endpoint was pathological complete response (pCR). Secondary endpoints included major pathological response (MPR), safety, survival, and other efficacy measures. Peripheral immune remodeling was assessed by flow cytometry, and bulk RNA sequencing of peripheral blood mononuclear cells (PBMCs) interrogated thymalfasin-associated transcriptional programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were enrolled and all underwent curative-intent minimally invasive gastrectomy. pCR was achieved in 30.0% (9\/30), and MPR in 56.7% (17\/30). ypN0 status was observed in 63.3% (19\/30), with N-stage downstaging in 80.0% (24\/30). At a median follow-up of 14.0\u00a0months (range 10.0\u201317.2), only one retroperitoneal nodal relapse had occurred at 14.4\u00a0months after diagnosis; no deaths were documented. Any-grade adverse events (AEs) occurred in 93.3% of patients, grade\u2009\u2265\u20093 AEs in 26.7%, and immune-related AEs in 23.3%. Flow cytometry showed expansion of CD8\u207a T cells with increased CD69 expression and a concurrent reduction in HLA-DR-positive T cells, suggesting dynamic remodeling from broad systemic activation toward a more focused effector or memory response. RNA-seq revealed thymalfasin-associated upregulation of genes involved in antigen processing and presentation, type I interferon signaling, and identified immune co-expression modules linked to treatment and response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant serplulimab, SOX, and thymalfasin produced encouraging pathological response, substantial nodal clearance, and an acceptable safety profile in stage III G\/EGJ adenocarcinoma. Peripheral immune and transcriptomic profiling are consistent with a hypothesis in which thymalfasin may help preserve and coordinate systemic antitumor immunity without excessive toxicity. These findings warrant further larger randomized trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT06461910, 2024\u201306-14.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04740-z","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:36:19Z","timestamp":1772102179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Hao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongda","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"1","key":"4740_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4740_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"10","key":"4740_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"key":"4740_CR4","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"issue":"9813","key":"4740_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321.","journal-title":"Lancet"},{"key":"4740_CR6","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer (2026). https:\/\/doi.org\/10.1007\/s10120-025-01698-4.","DOI":"10.1007\/s10120-025-01698-4"},{"key":"4740_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for Gastric Cancer V.2.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1434 (accessed May 25, 2025)."},{"issue":"26","key":"4740_CR8","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: a phase iii study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903\u201313.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4740_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4740_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4740_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","volume":"30","author":"YL Verschoor","year":"2024","unstructured":"Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat Med. 2024;30(2):519\u201330.","journal-title":"Nat Med"},{"issue":"7","key":"4740_CR12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498\u2013512.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4740_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"7903","key":"4740_CR14","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138.","journal-title":"Nature"},{"issue":"11","key":"4740_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4740_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33(1):74\u201382.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4740_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41578-023-00617-2","volume":"9","author":"L Xue","year":"2024","unstructured":"Xue L, Thatte AS, Mai D, Haley RM, Gong N, Han X, et al. Responsive biomaterials: optimizing control of cancer immunotherapy. Nat Rev Mater. 2024;9(2):100\u201318.","journal-title":"Nat Rev Mater"},{"key":"4740_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06716.x","volume":"1269","author":"L Romani","year":"2012","unstructured":"Romani L, Moretti S, Fallarino F, Bozza S, Ruggeri L, Casagrande A, et al. Jack of all trades: thymosin \u03b11 and its pleiotropy. Ann N Y Acad Sci. 2012;1269:1\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"4740_CR19","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","volume":"82","author":"YT Wei","year":"2022","unstructured":"Wei YT, Wang XR, Yan C, Huang F, Zhang Y, Liu X, et al. Thymosin \u03b1-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis. Cancer Res. 2022;82(10):1991\u20132002.","journal-title":"Cancer Res"},{"issue":"3","key":"4740_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ijrobp.2022.07.009","volume":"114","author":"F Liu","year":"2022","unstructured":"Liu F, Qiu B, Xi Y, Luo Y, Luo Q, Wu Y, et al. Efficacy of thymosin \u03b11 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: a phase 2 clinical trial (GASTO-1043). Int J Radiat Oncol Biol Phys. 2022;114(3):433\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"sup1","key":"4740_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14712598.2018.1494717","volume":"18","author":"R Danielli","year":"2018","unstructured":"Danielli R, Cisternino F, Giannarelli D, Calabr\u00f2 L, Camerini R, Savelli V, et al. Long-term follow up of metastatic melanoma patients treated with thymosin alpha-1: investigating immune checkpoints synergy. Expert Opin Biol Ther. 2018;18(sup1):77\u201383.","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"4740_CR22","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1517\/14712598.2015.1017466","volume":"15","author":"E Garaci","year":"2015","unstructured":"Garaci E, Pica F, Matteucci C, Gaziano R, D\u2019Agostini C, Miele MT, et al. Historical review on thymosin \u03b11 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):S31\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"4740_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101751","volume":"5","author":"K Liu","year":"2024","unstructured":"Liu K, Kong L, Cui H, Zhang L, Xin Q, Zhuang Y, et al. Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Reports Medicine. 2024;5(10):101751.","journal-title":"Cell Reports Medicine"},{"issue":"2 Pt B","key":"4740_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.canlet.2014.10.002","volume":"356","author":"C Ni","year":"2015","unstructured":"Ni C, Wu P, Wu X, Zhang T, Zhang T, Wang Z, et al. Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression. Cancer Lett. 2015;356(2 Pt B):579\u201388.","journal-title":"Cancer Lett"},{"issue":"5","key":"4740_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/BF02256128","volume":"11","author":"P Shrivastava","year":"2004","unstructured":"Shrivastava P, Singh SM, Singh N. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells. J Biomed Sci. 2004;11(5):623\u201330.","journal-title":"J Biomed Sci"},{"issue":"10294","key":"4740_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"2","key":"4740_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"21","key":"4740_CR28","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374.","journal-title":"JAMA"},{"issue":"2","key":"4740_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"SQ Yuan","year":"2024","unstructured":"Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30(2):552\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"4740_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li C, Tian Y, Zheng Y, Yuan F, Shi Z, Yang L, et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J Clin Oncol. 2025;43(4):464\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4740_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","volume":"15","author":"JX Lin","year":"2024","unstructured":"Lin JX, Tang YH, Zheng HL, Ye K, Cai JC, Cai LS, et al. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial. Nat Commun. 2024;15(1):41.","journal-title":"Nat Commun"},{"key":"4740_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635","author":"H Jiang","year":"2022","unstructured":"Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, et al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003635.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4740_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40480-x","volume":"14","author":"J Wei","year":"2023","unstructured":"Wei J, Lu X, Liu Q, Fu Y, Liu S, Zhao Y, et al. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nat Commun. 2023;14(1):4904.","journal-title":"Nat Commun"},{"issue":"5","key":"4740_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1674","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Li D, Zhuang J, Li Z, Xia Q, Li Z, et al. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial. Clin Transl Med. 2024;14(5):e1674.","journal-title":"Clin Transl Med"},{"issue":"3","key":"4740_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217\u201330.","journal-title":"N Engl J Med"},{"issue":"10","key":"4740_CR36","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"15","key":"4740_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2024.28463","volume":"333","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wang J, Wang G, Zhang Y, Fan Q, Lu C, et al. First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial. JAMA. 2025;333(15):1305\u201314.","journal-title":"JAMA"},{"issue":"4","key":"4740_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4740_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34403-5","volume":"13","author":"Z Tang","year":"2022","unstructured":"Tang Z, Wang Y, Liu D, Wang X, Xu C, Yu Y, et al. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 2022;13(1):6807.","journal-title":"Nat Commun"},{"issue":"7","key":"4740_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21(7):495\u2013508.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4740_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/gpbjnl\/qzaf072","volume":"23","author":"S Zhang","year":"2025","unstructured":"Zhang S, Chen X, Jin E, Wang A, Chen T, Zhang X, et al. The GSA family in 2025: a broadened sharing platform for multi-omics and multimodal data. Genomics Proteomics Bioinformatics. 2025;23(4):qzaf072.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"D1","key":"4740_CR42","doi-asserted-by":"publisher","first-page":"D30","DOI":"10.1093\/nar\/gkae978","volume":"53","author":"CNCB-NGDC Members and Partners","year":"2025","unstructured":"CNCB-NGDC Members and Partners. Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res. 2025;53(D1):D30\u201344.","journal-title":"Nucleic Acids Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04740-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04740-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04740-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:23:56Z","timestamp":1772724236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04740-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4740"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04740-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in strict accordance with the ethical standards outlined in the Declaration of Helsinki, GCP guidelines, and relevant local laws and regulations. Ethical approval was obtained from the Ethics Committee of First Affiliated Hospital of Nanjing Medical University (2024-SR-177). All patients provided written informed consent before participation, which included comprehensive information about study objectives, potential risks and benefits, procedures involved, confidentiality assurances, and the voluntary nature of participation. Patients retained the right to withdraw from the study at any time without affecting their future medical care. Patient data confidentiality was strictly maintained, and access to identifiable data was limited to authorized study personnel. Regular monitoring and audits were conducted to ensure compliance with the protocol and adherence to ethical guidelines throughout the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The reporting of this trial adheres to the CONSORT guidelines (Additional file 4: CONSORT checklist). All authors have read and approved the final version of the manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}